Glenmark receives ANDA approval for generic version of Temovate Cream

11 May 2018 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Clobetasol Propionate Cream USP, 0.05%, the generic version of Temovate Cream, 0.05%, of Fougera Pharmaceuticals, Inc.

According to IQVIA sales data for the 12 month period ending March 2018, the Temovate Cream, 0.05% market achieved annual sales of approximately $118.0 million.

Glenmark’s current portfolio consists of 134 products authorized for distribution in the US marketplace and 61 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharma Share Price

2003.50 32.75 (1.66%)
27-Jan-2026 15:19 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.95
Dr. Reddys Lab 1239.40
Cipla 1312.60
Zydus Lifesciences 894.35
Lupin 2151.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×